TLR7 and neoplasm: In cervical cancer, lung cancer and melanoma models, tumor antigens adjuvant with nanoemulsion (NE) loaded with TLR7/8 agonists showed enhanced infiltration of lymphocytes, polarization of tumor-associated M2 macrophages, strong local and systemic anti-tumor immune response, resulting in inhibited tumor growth and prolonged survival [139, 140].